NYSE:DHR

Danaher (DHR) Stock Forecast, Price & News

$234.53

+1.84 (+0.79%)

(As of 06/2/2023 ET)

Compare

Today's Range: $232.27
▼
$235.81
50-Day Range: $224.99
▼
$256.14
52-Week Range: $221.22
▼
$303.82

Volume: 2.23 million shs
Average Volume: 2.96 million shs
Market Capitalization: $173.06 billion

P/E Ratio: 25.27
Dividend Yield: 0.46%
Price Target: $294.06

Danaher MarketRank™ Forecast

Analyst Rating: Moderate Buy
2.82 Rating Score
Upside/Downside: 25.4% Upside
$294.06 Price Target
Short Interest: Healthy
0.61% of Float Sold Short
Dividend Strength: Moderate
Based on Four Factors
Sustainability: -1.11
Upright™ Environmental Score
News Sentiment: 0.20
Based on 9 Articles This Week
Insider Trading: Selling Shares
$8.10 M Sold Last Quarter
Proj. Earnings Growth: 9.00%
From $9.44 to $10.29 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

3.42 out of 5 stars

Multi-Sector Conglomerates Sector

1st out of 19 stocks

Process Control Instruments Industry

1st out of 11 stocks

4.4

Analyst's Opinion

Consensus Rating
Danaher has received a consensus rating of Buy. The company's average rating score is 2.82, and is based on 14 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $294.06, Danaher has a forecasted upside of 25.4% from its current price of $234.53.
Amount of Analyst Coverage
Danaher has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

5.0

Short Interest

Percentage of Shares Shorted
0.61% of the float of Danaher has been sold short.
Short Interest Ratio / Days to Cover
Danaher has a short interest ratio ("days to cover") of 1.4, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Danaher has recently decreased by 11.02%, indicating that investor sentiment is improving significantly.

2.5

Dividend Strength

Dividend Yield
Danaher has a dividend yield of 0.47%, which is in the bottom 25% of all stocks that pay dividends.
Dividend Growth
Danaher has been increasing its dividend for 7 years.
Dividend Coverage
The dividend payout ratio of Danaher is 11.64%. This payout ratio is at a healthy, sustainable level, below 75%.
Dividend Sustainability
Based on earnings estimates, Danaher will have a dividend payout ratio of 10.50% next year. This indicates that Danaher will be able to sustain or increase its dividend.

4.1

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Danaher has received a 57.99% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Plasmid DNA", "Cell analysis systems", "Oligonucleotides", "Medical imaging software", "Colorimetric analysis kits", and "CRISPR gene-editing tools" products. See details.
Environmental Sustainability
The Environmental Impact score for Danaher is -1.11.

2.3

News and Social Media Coverage

News Sentiment
Danaher has a news sentiment score of 0.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.63 average news sentiment score of Multi-Sector Conglomerates companies.
News Coverage This Week
MarketBeat has tracked 9 news articles for Danaher this week, compared to 8 articles on an average week.
Search Interest
Only 41 people have searched for DHR on MarketBeat in the last 30 days. This is a decrease of -28% compared to the previous 30 days.
MarketBeat Follows
19 people have added Danaher to their MarketBeat watchlist in the last 30 days. This is an increase of 58% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Danaher insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $8,103,781.00 in company stock.
Percentage Held by Insiders
11.10% of the stock of Danaher is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
77.26% of the stock of Danaher is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.9

Earnings and Valuation

Earnings Growth
Earnings for Danaher are expected to grow by 9.00% in the coming year, from $9.44 to $10.29 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Danaher is 25.27, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.71.
Price to Earnings Ratio vs. Sector
The P/E ratio of Danaher is 25.27, which means that it is trading at a more expensive P/E ratio than the Multi-Sector Conglomerates sector average P/E ratio of about 6.31.
Price to Earnings Growth Ratio
Danaher has a PEG Ratio of 2.32. PEG Ratios above 1 indicate that a company could be overvalued.
Price to Book Value per Share Ratio
Danaher has a P/B Ratio of 3.47. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Danaher (NYSE:DHR) Stock

Danaher Corp. engages in the design, manufacture, and marketing of professional, medical, industrial, and commercial products and services. It operates through the following segments: Biotechnology, Life Sciences, Diagnostics, and Environmental and Applied Solutions. The Biotechnology segment includes the bioprocessing and discovery and medical businesses and offers a range of tools, consumables, and services. The Life Sciences segment offers a range of instruments and consumables to study the basic building blocks of life, including DNA and RNA. The Diagnostics segment offers clinical instruments, reagents, consumables, software, and services used to diagnose disease and make treatment decisions. The Environmental and Applied Solution segment offers products and services that help protect important resources and keep global food and water supplies safe. The company was founded by Steven M. Rales and Mitchell P. Rales in 1984 and is headquartered in Washington, DC.

Receive DHR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Danaher and its competitors with MarketBeat's FREE daily newsletter.

DHR Stock News Headlines

June 2, 2023 | americanbankingnews.com

Danaher Co. (NYSE:DHR) SVP Daniel Raskas Sells 19,847 Shares of Stock

June 2, 2023 | americanbankingnews.com

Zacks Research Comments on Danaher Co.'s Q2 2023 Earnings (NYSE:DHR)

June 2, 2023 | Stocks To Trade (Ad)

15 A.I. Trading Opportunities a Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 31, 2023 | msn.com

Danaher Unusual Options Activity

May 30, 2023 | finance.yahoo.com

Danaher (NYSE:DHR) shareholders have earned a 18% CAGR over the last five years

May 24, 2023 | msn.com

If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,900 Today

May 24, 2023 | seekingalpha.com

Danaher: Not Attractive Now, Experiencing Headwinds

May 23, 2023 | seekingalpha.com

Danaher: Bioprocessing Should Drive Long-Term Growth

June 2, 2023 | Stocks To Trade (Ad)

15 A.I. Trading Opportunities a Day

Using our algorithm, we sift through 15,000 stocks every second. We generate 15 trading opportunities a day.

May 23, 2023 | seekingalpha.com

Danaher: A Great Chance To Buy This Long-Term Compounder

May 19, 2023 | benzinga.com

Danaher Stock (NYSE:DHR), Insider Trading Activity

May 18, 2023 | finance.yahoo.com

Is Danaher (NYSE:DHR) Using Too Much Debt?

May 18, 2023 | fool.com

Danaher (NYSE: DHR)

May 18, 2023 | americanbankingnews.com

StockNews.com Initiates Coverage on Danaher (NYSE:DHR)

May 17, 2023 | msn.com

(DHR) - Analyzing Danaher's Short Interest

May 15, 2023 | finance.yahoo.com

Beckman Coulter Unveils Next Generation Immunoassay Analyzer Enabling Elite Laboratory Performance with No Daily Maintenance

May 14, 2023 | marketwatch.com

Trading Danaher $DHR With Integrated Risk Controls

May 14, 2023 | seekingalpha.com

Danaher Corporation (DHR) Bank of America Securities 2023 Healthcare Conference Transcript

May 14, 2023 | americanbankingnews.com

Danaher Co. Expected to Earn Q2 2023 Earnings of $2.02 Per Share (NYSE:DHR)

May 12, 2023 | americanbankingnews.com

Brokerages Set Danaher Co. (NYSE:DHR) Target Price at $294.06

May 11, 2023 | msn.com

Danaher (DHR) Declares $0.27 Dividend

May 11, 2023 | americanbankingnews.com

Danaher Co. (DHR) To Go Ex-Dividend on June 29th

May 11, 2023 | americanbankingnews.com

Danaher Co. (NYSE:DHR) Director Sells $840,671.20 in Stock

May 10, 2023 | marketwatch.com

Danaher Corp. stock falls Tuesday, underperforms market

May 10, 2023 | thestreet.com

Pall Corp. (PLL) Stock Jumping on $13.8 Billion Danaher Takeover

May 10, 2023 | msn.com

Danaher Unusual Options Activity For May 10

May 10, 2023 | marketwatch.com

Danaher Corp. stock falls Wednesday, underperforms market

See More Headlines

DHR Price History

30 days | 90 days | 365 days | Advanced Chart

DHR Company Calendar

Ex-Dividend for 4/28 Dividend: 3/30/2023
Last Earnings: 4/25/2023
Dividend Payable: 4/28/2023
Today: 6/02/2023
Ex-Dividend for 7/28 Dividend: 6/29/2023
Next Earnings (Estimated): 7/20/2023
Dividend Payable: 7/28/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Process control instruments
Sub-Industry: Industrial Conglomerates
Sector: Multi-Sector Conglomerates
Current Symbol: NYSE:DHR
CUSIP: 23585110
CIK: 313616
Web: www.danaher.com
Phone: (202) 828-0850
Fax: 202-828-0860
Employees: 81,000
Year Founded: 1984

Price Target and Rating

Average Stock Price Forecast: $294.06
High Stock Price Forecast: $340.00
Low Stock Price Forecast: $250.00
Forecasted Upside/Downside: +25.3%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.82
Research Coverage: 17 Analysts

Profitability

EPS (Most Recent Fiscal Year): $9.28
Trailing P/E Ratio: 25.29
Forward P/E Ratio: 24.86
P/E Growth: 2.32
Net Income: $7.21 billion
Net Margins: 22.40%
Pretax Margin: 25.82%
Return on Equity: 16.70%
Return on Assets: 9.47%

Debt

Debt-to-Equity Ratio: 0.37
Current Ratio: 1.89
Quick Ratio: 1.51

Sales & Book Value

Annual Sales: $31.47 billion
Price / Sales: 5.50
Cash Flow: $14.58 per share
Price / Cash Flow: 16.10
Book Value: $67.51 per share
Price / Book: 3.48

Miscellaneous

Outstanding Shares: 737,900,000
Free Float: 655,992,000
Market Cap: $173.16 billion
Optionable: Optionable
Beta: 0.80

Social Links

Key Executives

Rainer M. Blair
President, Chief Executive Officer & Director

Matthew R. McGrew
Chief Financial Officer & Executive Vice President

Jose-Carlos Gutiérrez-Ramos
Chief Science Officer & Senior Vice President

Sadik Kassim
Chief Technology Officer

Brian W. Ellis
Senior Vice President & General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

DHR Stock - Frequently Asked Questions

Should I buy or sell Danaher stock right now?: 17 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Danaher in the last twelve months. There are currently 3 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DHR shares.
View DHR analyst ratings or view top-rated stocks.
What is Danaher's stock price forecast for 2023?: 17 equities research analysts have issued 1-year price targets for Danaher's stock. Their DHR share price forecasts range from $250.00 to $340.00. On average, they predict the company's stock price to reach $294.06 in the next year. This suggests a possible upside of 25.2% from the stock's current price.
View analysts price targets for DHR or view top-rated stocks among Wall Street analysts.
How have DHR shares performed in 2023?: Danaher's stock was trading at $265.42 at the beginning of the year. Since then, DHR stock has decreased by 11.5% and is now trading at $234.85.
View the best growth stocks for 2023 here.
Are investors shorting Danaher?: Danaher saw a drop in short interest in May. As of May 15th, there was short interest totaling 4,120,000 shares, a drop of 11.0% from the April 30th total of 4,630,000 shares. Based on an average daily volume of 2,940,000 shares, the days-to-cover ratio is presently 1.4 days. Currently, 0.6% of the company's shares are sold short.
View Danaher's Short Interest.
When is Danaher's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, July 20th 2023.
View our DHR earnings forecast.
How were Danaher's earnings last quarter?: Danaher Co. (NYSE:DHR) issued its quarterly earnings results on Tuesday, April, 25th. The conglomerate reported $2.36 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $2.26 by $0.10. The conglomerate had revenue of $7.17 billion for the quarter, compared to the consensus estimate of $7.06 billion. Danaher had a net margin of 22.40% and a trailing twelve-month return on equity of 16.70%. The firm's quarterly revenue was down 6.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $2.76 EPS.
Read the conference call transcript.
How often does Danaher pay dividends? What is the dividend yield for Danaher?: Danaher declared a quarterly dividend on Tuesday, May 9th. Stockholders of record on Friday, June 30th will be paid a dividend of $0.27 per share on Friday, July 28th. This represents a $1.08 dividend on an annualized basis and a yield of 0.46%. The ex-dividend date of this dividend is Thursday, June 29th.
Read our dividend analysis for DHR.
What ETFs hold Danaher's stock?: ETFs with the largest weight of Danaher (NYSE:DHR) stock in their portfolio include Invesco Water Resources ETF (PHO), Invesco Global Water ETF (PIO), Alpha Intelligent - Large Cap Growth ETF (AILG), Franklin Genomic Advancements ETF (HELX), Putnam BioRevolution ETF (SYNB), God Bless America ETF (YALL), Pacer BioThreat Strategy ETF (VIRS) and Natixis Vaughan Nelson Select ETF (VNSE).
Is Danaher a good dividend stock?: Danaher (NYSE:DHR) pays an annual dividend of $1.08 per share and currently has a dividend yield of 0.47%. The company has been increasing its dividend for 7 consecutive years, indicating the company has a new, but growing committment to grow its dividend. The dividend payout ratio is 11.64%. This payout ratio is at a healthy, sustainable level, below 75%. Based on earnings estimates, DHR will have a dividend payout ratio of 10.50% next year. This indicates that the company will be able to sustain or increase its dividend.
Read our dividend analysis for DHR.

What is Rainer M. Blair's approval rating as Danaher's CEO?: 27 employees have rated Danaher Chief Executive Officer Rainer M. Blair on Glassdoor.com. Rainer M. Blair has an approval rating of 98% among the company's employees. This puts Rainer M. Blair in the top 20% of approval ratings compared to other CEOs of publicly-traded companies.
What other stocks do shareholders of Danaher own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Danaher investors own include NVIDIA (NVDA), Home Depot (HD), Walt Disney (DIS), Johnson & Johnson (JNJ), Adobe (ADBE), Intel (INTC), Alibaba Group (BABA), Mastercard (MA), PayPal (PYPL) and AbbVie (ABBV).
What is Danaher's stock symbol?: Danaher trades on the New York Stock Exchange (NYSE) under the ticker symbol "DHR."
Who are Danaher's major shareholders?: Danaher's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include State Street Corp (3.67%), Geode Capital Management LLC (1.75%), Bank of New York Mellon Corp (1.01%), Aristotle Capital Management LLC (0.67%), Fisher Asset Management LLC (0.55%) and Charles Schwab Investment Management Inc. (0.49%). Insiders that own company stock include Alan G Spoon, Angela S Lalor, Angela S Lalor, Brian W Ellis, Daniel L Comas, Daniel Raskas, Elias A Zerhouni, Georgeann Couchara, Jennifer Honeycutt, Joakim Weidemanis, John T Schwieters, Jose-Carlos Gutierrez-Ramos, Linda P Hefner, Matthew Mcgrew, Mitchell P Rales, Rainer Blair, Raymond C Stevens, Robert S Lutz, Teri List, Thomas Patrick Joyce Jr, Walter G Lohr and William King.
View institutional ownership trends.
How do I buy shares of Danaher?: Shares of DHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Danaher's stock price today?: One share of DHR stock can currently be purchased for approximately $234.85.
How much money does Danaher make?: Danaher (NYSE:DHR) has a market capitalization of $173.30 billion and generates $31.47 billion in revenue each year. The conglomerate earns $7.21 billion in net income (profit) each year or $9.28 on an earnings per share basis.
How many employees does Danaher have?: The company employs 81,000 workers across the globe.
Does Danaher have any subsidiaries?: The following companies are subsidiares of Danaher: AB SCIEX, AB Sciex LLC, AB Sciex LP, AB Sciex Pte Ltd., Accu-Sort Systems, Acme Cleveland Corporation, Advanced Vision Technology, Aldevron, Aldevron L.L.C., American Precision Industries, Applied Biosystems, Applitek NV, Aquatic Infomatics ULC, Aquatic Informatics, Armstrong Tools, BC Distribution BV, Beckman Coulter, Beckman Coulter Australia Pty Ltd, Beckman Coulter Biotechnology Suzhou Co. Ltd., Beckman Coulter Canada LP, Beckman Coulter Commercial Enterprise China Co. Ltd., Beckman Coulter France S.A.S., Beckman Coulter G.m.b.H., Beckman Coulter Genomics Inc., Beckman Coulter Hong Kong Limited, Beckman Coulter Inc., Beckman Coulter India Private Limited, Beckman Coulter International SA, Beckman Coulter International Shanghai Trading Co., Beckman Coulter Ireland Inc., Beckman Coulter K.K., Beckman Coulter Korea Ltd, Beckman Coulter Laboratory Systems Suzhou Co. Ltd., Beckman Coulter Limited Liability Company, Beckman Coulter Nederland B.V., Beckman Coulter Nippon GK, Beckman Coulter S.L.U., Beckman Coulter Saudi Arabia Co.Ltd., Beckman Coulter Srl, Beckman Coulter Taiwan Inc., Beckman Coulter United Kingdom Limited, Beckman Coulter de Mexico S.A. de C.V., Beckman Finance ApS, Biacore International AB, Biosafe S.A., Blue Software LLC, Cepheid, Cepheid AB, Cepheid Canada ULC, Cepheid Europe SAS, Cepheid GmbH, Cepheid HBDC SAS, Cepheid India Private Limited, Cepheid UK Ltd., ChemTreat, ChemTreat Inc., Cispus Hong Kong Holding Limited, Cytiva, Cytiva BioProcess R&D AB, Cytiva Biotechnology Guangzhou Co. Ltd., Cytiva Biotechnology Hang Zhou Co. Ltd., Cytiva Europe GmbH, Cytiva Sweden AB, DCHL Holding BV, DH Denmark Holding ApS, DH Europe Finance II Sarl, DH Europe Finance Sarl, DH Holding Italia SRL, DH Holdings Germany LLC, DH II Luxembourg Sarl, DH Japan Finance Sarl, DH Switzerland Finance Sarl, DH Technologies Development Pte Ltd., DHCY Limited, DHKAB Company AB, DTIL Ireland Holdings Ltd., Danaher China Holdings Ltd., Danaher Finance Company AB, Danaher HK Holdings Ltd., Danaher Medical ApS, Danaher Shanghai Management Co. Ltd., Delta Consolidated Industries, Devicore Medical Products Inc., Easco Hand Tools, Esko, Esko BV, Esko Graphics BV, Esko Graphics Inc., Esko Software BV, Fluke, GE Biopharma, Gelman Sciences Inc., Gendex, Genetix Group, Gilbarco Veeder Root, Gilzoni Ltd., Global Life Sciences Solutions Austria GmbH & Co. KG, Global Life Sciences Solutions Germany GmbH, Global Life Sciences Solutions Korea Ltd., Global Life Sciences Solutions Manufacturing UK Ltd, Global Life Sciences Solutions Operations UK Ltd, Global Life Sciences Solutions Singapore Pte Ltd, Global Life Sciences Solutions USA LLC, Global Life Sciences Technologies Japan KK, Global Life Sciences Technologies Shanghai Co Ltd., Hach Company, Hach Lange GmbH, Hach Lange Sàrl, Hach Water Quality Analytical Instru. Shanghai Co. Ltd., HemoCue AB, HyClone Laboratories LLC, Hybritech Incorporated, Hyclone Life Sciences Solutions India Private Limited, ID Business Solutions Limited, IDBS Group, IRIS International, Imaging Sciences International, Immunotech Sro, Intabio LLC, Integrated DNA Technologies, Integrated DNA Technologies BVBA, Integrated DNA Technologies Inc., Integrated DNA Technologies Pte. Ltd., Intermountain Life Sciences LLC, Iris International Inc., KaVo, KaVo Kerr, Kaltenbach & Voigt, Keithley Instruments, Kipp & Zonen BV, Kollmorgen, Labcyte Inc., Laetus, Launchchange Holding Company, Leica Biosystems Imaging Inc., Leica Biosystems Melbourne Pty Ltd, Leica Biosystems Newcastle Limited, Leica Biosystems Nussloch GmbH, Leica Biosystems Richmond Inc., Leica Instruments Singapore Pte Limited, Leica Microsystems, Leica Microsystems CMS GmbH, Leica Microsystems Cambridge Limited, Leica Microsystems IR GmbH, Leica Microsystems Inc., Leica Microsystems Limited, Leica Microsystems UK Limited, Leica Mikrosysteme GmbH, Leica Mikrosysteme Vertrieb GmbH, Life Sciences Holdings France SAS, Life Sciences IP Holdings Corporation, Lifschultz Industries, Linx Printing Technologies, Linx Printing Technologies Limited, MDS Analytical Technologies, Marconi Data Systems, Microtest, Molecular Devices, Molecular Devices LLC, Navman Wireless, Navman Wireless OEM Solutions, Nihon Pall Ltd., Nobel Biocare, OTT Hydromet Corp, Pall Aeropower Corporation, Pall Artelis BVBA, Pall Asia Holdings Inc., Pall Austar Lifesciences Limited, Pall Australia Pty. Ltd., Pall Austria Filter Ges.m.b.h, Pall Canada ULC, Pall China Co. Ltd., Pall Corporation, Pall Europe Limited, Pall Filtersystems GmbH, Pall Filtration Pte. Ltd., Pall Filtration and Separations Group Inc., Pall France SAS, Pall GmbH, Pall India Pvt. Ltd., Pall International Sarl, Pall Italia Srl, Pall Korea Ltd., Pall Life Sciences Belgium BV, Pall Life Sciences Puerto Rico LLC, Pall Manufacturing UK Limited, Pall Medistad BV, Pall Netherlands BV Irish Branch, Pall Schweiz GmbH, Pall Technology UK Limited, PaloDEX, Pantone LLC, Pelton & Crane, Phenomenex, Phenomenex Inc., Precision NanoSystems, Precision Nanosystems ULC, Radiometer, Radiometer Medical ApS, Radiometer Turku Oy, Raytek, Reytek Corporation, Sea-Bird Electronics Inc., Sedaru Inc., Shanghai AB Sciex Analytical Instrument Trading Co. Ltd., Skyland Analytics Inc., Sutron, Swift Biosciences Inc., Sybron Dental Specialties, Tektronix, Thomson Industries, Trojan Technologies, Trojan Technologies Group ULC, VSS Monitoring, Vanrx Pharmasystems Inc., Videojet Do Brasil Comércio de Equipamentos Para Codificação Industrial Ltda., Videojet Technologies Europe B.V., Videojet Technologies GmbH, Videojet Technologies Inc., Videojet Technologies S Pte.Ltd., Viridor Waste Management Limited, Vision Systems Limited, Willett International, X-Ray Optical Systems Inc., X-Rite, X-Rite Europe GmbH, X-Rite Incorporated, XOS, Yukon Hong Kong Holding Limited, and Zhuhai S.E.Z. Videojet Electronics Ltd..
Read More
How can I contact Danaher?: Danaher's mailing address is 2200 PENNSYLVANIA AVE. N.W SUITE 800W, WASHINGTON DC, 20037. The official website for the company is www.danaher.com. The conglomerate can be reached via phone at (202) 828-0850, via email at investor.relations@danaher.com, or via fax at 202-828-0860.

This page (NYSE:DHR) was last updated on 6/2/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial